Total
0
Shares
Clover Corporation (ASX:CLV) sees 23.6pc profit growth in FY20
  • Microencapsulation technology company Clover Corporation (CLV) has seen a 23.6 per cent profit growth for the 2020 financial year ending July 31
  • Clover's revenue also improved - with a 15.1 per cent increase from $76.7 million in 2019 to $88.3 million in FY20
  • COVID-19 had very little negative impacts on the company
  • In fact, Clover experienced a higher demand to supply more infant formula as a result of panic buying
  • Shareholders will also see a final dividend of 2.5 cents per share which will be paid on November 18
  • Despite the positive results, Clover has seen an 8.57 per cent drop in its share price and is now trading for $2.24

Microencapsulation technology company Clover Corporation (CLV) has seen a 23.6 per cent profit growth for the financial year ending July 31 2020.

Clover has shifted from being a research, development, manufacturing and marketing company to concentrate on forming strategic relationships based on technology, and developing and commercialising new products.

The company's microencapsulation technology allows nutritional oils, such as tuna, fish, algal and fungal oils, to be added to infant formula, foods and beverages.

Clover's revenue for the year was roughly $88.3 million, which is an increase of 15.1 per cent on 2019's $76.7 million. Net profit after tax came in at $12.5 million, a 23.6 per cent increase from last year's $10.1 million.

The improved result can be attributed to new customers, new products and territorial expansion.

According to Clover, COVID-19 was no hinder to operations. In fact, it actually helped to increase the demand from clients wanting more infant formula due to panic buying in retail outlets.

However, its new customer deployment has been held back due to the inability to travel, perform audits or attend trade shows. In the U.S., new product development has been on hold due to resources being focused on other activities.

Overall expenses have been contained during 2020 at $11.4 million, which is higher than last year's $10.6 million.

During the 2020 financial year, Clover experienced revenue growth across all markets. Australia, New Zealand and Asian markets have continued to grow, mainly due to the demand of baby formula and an increased interest in the health benefits of Omega 3.

In 2019, the company invested in a new company, Melody Dairies, which has developed a nutritional spray dryer in Hamilton, New Zealand. Clover owns 42 per cent of the dryer and has access to 42 per cent of its capacity to manufacture its products.

Shareholders will also see a final dividend of 2.5 cents per share, to be paid on November 18.

Despite the positive results, Clover has seen an 8.57 per cent drop in its share price and is now trading for $2.24 at 2:22 pm AEST.


Subscribe


CLV by the numbers
More From The Market Herald
Piedmont Lithium (ASX:PLL) - President & CEO, Keith D Phillips - The Market Herald

" Piedmont Lithium (ASX:PLL) raises $70M to develop American lithium project

Piedmont Lithium (PLL) has raised around $70 million in a U.S. public offering to continue development of its namesake project in Carolina, U.S.
Valor Resources (ASX:VAL) - Executive Chairman, George Bauk - The Market Herald

" Valor Resources (ASX:VAL) nabs Canadian uranium assets

Valor Resources (VAL) bolstered its landholding today, adding two uranium assets to its project portfolio.
Australian Vanadium (ASX:AVL) - Managing Director, Vincent Algar - The Market Herald

" Australian Vanadium (ASX:AVL) teams with GSA for vanadium feedstocks

Australian Vanadium (AVL) has signed a memorandum of understanding (MOU) with GSA Environmental (GSAe) to develop the Australian Vanadium Project in WA.
Rafaella Resources (ASX:RFR) review of proposed Canada projects yields strong results

" Rafaella Resources (ASX:RFR) review of proposed Canada projects yields strong results

Rafaella Resources (RFR) has been advised an initial review of one of its proposed Canadian projects has been completed and returned positive results.